HEALTHSTORY 545· AUGUST 7, 2026

FDA clears Replimune's melanoma drug Tudriqev after two rejections

A cancer treatment rejected twice by federal regulators has now won approval. The Food and Drug Administration granted accelerated approval to Tudriqev, a drug made by the biotech company Replimune, for patients with advanced melanoma…

NDNewsDialy Desk2 MIN READ

SOURCE

statnews.com

← PREVIOUS STORY 544Democrats' Midwest primary battle intensifies after El-Sayed win in Michigan NEXT STORY 546 →Chelsea Gray hits two buzzer-beaters as Las Vegas Aces outlast Indiana Fever in overtime at Gainbridge Fieldhouse

Keep reading

More from the desk.

22HEALTH

Pennsylvania records fourth measles death, an 18-year-old from Mifflin County

Pennsylvania has now reported a fourth death connected to measles. The latest was an 18-year-old resident of Mifflin County, in the center of the state, who died from acute disseminated encephalomyelitis, a rare and severe neurological…

health1 MIN

34HEALTH

Novartis shares drop 11% on drug failure as biosimilar gap threatens $200 billion in savings

A failed clinical trial wiped nearly $30 billion from Novartis's market value this week after shares fell 11% in a single session, erasing all the gains the stock had made since the start of the year. The drug that failed, del-desiran, was…

health2 MIN

42HEALTH

EU legal adviser hands pharma a win on wastewater costs

Pharmaceutical and cosmetics companies across Europe may be off the hook for the largest share of a continent-wide water cleanup effort, after a legal adviser to the EU's top court recommended striki

health2 MIN

Tomorrow · 06:00

Start tomorrow already ahead.

Five stories, a two-minute read, zero noise — the world before your first coffee.

Get the 6AM brief Back to the desk